155 related articles for article (PubMed ID: 17211884)
1. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.
Schlee M; Hölzel M; Bernard S; Mailhammer R; Schuhmacher M; Reschke J; Eick D; Marinkovic D; Wirth T; Rosenwald A; Staudt LM; Eilers M; Baran-Marszak F; Fagard R; Feuillard J; Laux G; Bornkamm GW
Int J Cancer; 2007 Apr; 120(7):1387-95. PubMed ID: 17211884
[TBL] [Abstract][Full Text] [Related]
2. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
3. Regressing nude mouse grafts of Burkitt's lymphoma x lymphoblastoid cell hybrids show deregulation of the c-myc gene and expression of the EBV latent membrane protein.
Wolf J; Klevenz B; Pawlita M; Komitowski D; Moldenhauer G; zur Hausen H
Int J Cancer; 1991 Jan; 47(1):99-104. PubMed ID: 1702406
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
5. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
6. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
8. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
9. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
10. The Epstein-Barr virus nuclear antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphoma cell lines.
Kanda K; Kempkes B; Bornkamm GW; von Gabain A; Decker T
Biol Chem; 1999 Feb; 380(2):213-21. PubMed ID: 10195428
[TBL] [Abstract][Full Text] [Related]
11. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
12. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
13. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
14. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
16. Induction of IκB-ζ by Epstein-Barr virus latent membrane protein-1 and CD30.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2015 Dec; 47(6):2197-207. PubMed ID: 26498461
[TBL] [Abstract][Full Text] [Related]
17. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
18. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
19. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
20. Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells.
Najjar I; Baran-Marszak F; Le Clorennec C; Laguillier C; Schischmanoff O; Youlyouz-Marfak I; Schlee M; Bornkamm GW; Raphaël M; Feuillard J; Fagard R
J Virol; 2005 Apr; 79(8):4936-43. PubMed ID: 15795279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]